Skip to Content

PT Kalbe Farma Tbk LCLA

Morningstar Rating
IDR 0.07 0.00 (0.67%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LCLA is trading at a 882% premium.
Price
€0.08
Fair Value
€5.45
Uncertainty
High
1-Star Price
€1.87
5-Star Price
€6.92
Economic Moat
Jfcgqpz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LCLA is a good fit for your portfolio.

Trading Information

Previous Close Price
IDR 0.08
Day Range
IDR 0.070.09
52-Week Range
IDR 0.040.19
Bid/Ask
IDR 0.00 / IDR 0.00
Market Cap
IDR 3.45 Bil
Volume/Avg
11,500 /

Key Statistics

Price/Earnings (Normalized)
20.06
Price/Sales
1.88
Dividend Yield (Trailing)
50,666.67%
Dividend Yield (Forward)
3.15%
Total Yield
50,666.67%

Company Profile

PT Kalbe Farma Tbk is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. Majority of the company's gross profits are derived from the distribution and logistics segments. The company operates in Indonesia but has operations across various ASEAN countries, Nigeria, and South Africa.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
13,062

Comparables

Valuation

Metric
LCLA
EPMT
271980
Price/Earnings (Normalized)
20.069.3037.33
Price/Book Value
2.660.891.56
Price/Sales
1.880.230.34
Price/Cash Flow
15.1516.5715.76
Price/Earnings
LCLA
EPMT
271980

Financial Strength

Metric
LCLA
EPMT
271980
Quick Ratio
2.451.410.63
Current Ratio
4.312.601.00
Interest Coverage
48.5061.241.15
Quick Ratio
LCLA
EPMT
271980

Profitability

Metric
LCLA
EPMT
271980
Return on Assets (Normalized)
10.44%6.42%1.45%
Return on Equity (Normalized)
13.70%9.68%4.28%
Return on Invested Capital (Normalized)
12.05%9.52%4.70%
Return on Assets
LCLA
EPMT
271980
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoCbxdlsgxFyscj$733.3 Bil
JNJ
Johnson & JohnsonJhjwgnxSbbs$360.8 Bil
MRK
Merck & Co IncSxfncvnfrZhbz$329.8 Bil
ABBV
AbbVie IncTrjgcqrxBpykr$283.3 Bil
AZN
AstraZeneca PLC ADRKzjmzhfnkCfnrw$237.7 Bil
NVS
Novartis AG ADRZqjyzcccSjcg$203.4 Bil
RHHBY
Roche Holding AG ADRHzhyllpyYxdy$197.6 Bil
AMGN
Amgen IncWplvrrvmgNdvg$166.4 Bil
PFE
Pfizer IncLvwcplpJgr$159.7 Bil
SNY
Sanofi SA ADRJfjtnwstGgr$125.1 Bil

Sponsor Center